MX362819B - Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. - Google Patents

Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.

Info

Publication number
MX362819B
MX362819B MX2015009154A MX2015009154A MX362819B MX 362819 B MX362819 B MX 362819B MX 2015009154 A MX2015009154 A MX 2015009154A MX 2015009154 A MX2015009154 A MX 2015009154A MX 362819 B MX362819 B MX 362819B
Authority
MX
Mexico
Prior art keywords
narcolepsy
treatment
receptor agonists
alpha
nicotinic receptor
Prior art date
Application number
MX2015009154A
Other languages
English (en)
Other versions
MX2015009154A (es
Inventor
Baltazar Gomez-Mancilla
Dominik Feuerbach
Markus Fendt
Cristina Lopez-Lopez
Kevin Hall Mcallister
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2015009154A publication Critical patent/MX2015009154A/es
Publication of MX362819B publication Critical patent/MX362819B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere al uso de ciertos agonistas del receptor nicotínico de acetilcolina alfa 7 para uso en el tratamiento, mejora, prevención o retraso del avance de la narcolepsia, la somnolencia excesiva durante el día, la perturbación del sueño nocturno y/o la cataplexia.
MX2015009154A 2013-01-15 2013-01-15 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia. MX362819B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/050368 WO2014111751A1 (en) 2013-01-15 2013-01-15 Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy

Publications (2)

Publication Number Publication Date
MX2015009154A MX2015009154A (es) 2016-03-04
MX362819B true MX362819B (es) 2019-02-18

Family

ID=47747729

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009154A MX362819B (es) 2013-01-15 2013-01-15 Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.

Country Status (9)

Country Link
EP (1) EP2945626B1 (es)
JP (1) JP6137336B2 (es)
KR (1) KR101879921B1 (es)
CN (1) CN105263492B (es)
BR (1) BR112015016994A8 (es)
CA (1) CA2898043C (es)
ES (1) ES2701083T3 (es)
MX (1) MX362819B (es)
WO (1) WO2014111751A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028440A1 (en) * 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2020163405A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
WO2004016608A1 (en) * 2002-08-14 2004-02-26 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
EE05516B1 (et) * 2002-09-25 2012-02-15 Memory@Pharmaceuticals@Corporation Indasoolid bensotiasoolid ja bensoisotiasoolid nende valmistamine ning kasutamine
EP1677790A1 (en) 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
WO2005044265A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
CN1870999A (zh) 2003-10-31 2006-11-29 阿斯利康(瑞典)有限公司 炔烃ⅰ
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
EP1715867A4 (en) 2004-02-12 2009-04-15 Merck & Co Inc BIPYRIDYL AMIDES AS MODULATORS OF GLUTAMATE METABOTROPIC REPEATER-5
GB0412019D0 (en) 2004-05-28 2004-06-30 Novartis Ag Organic compounds
AR049401A1 (es) * 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008538417A (ja) 2005-04-08 2008-10-23 エクステラス インコーポレイテッド 多重チャンネル波長分散補償器
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP2009519986A (ja) 2005-12-20 2009-05-21 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体のモジュレーターとしてのニコチン酸誘導体
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
CN102516241B (zh) 2006-05-19 2015-07-29 艾伯维巴哈马有限公司 Cns活性的稠合的双环杂环取代的氮杂双环烷烃衍生物
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
BRPI0920187A2 (pt) 2008-10-13 2019-08-27 Hoffmann La Roche método sem diazônio para fabricar um indazol intermediário na síntese de amidas bicíclicas do ácido 5-(triflúor-metóxi)-1h-3-indazol-carboxílico
EP2364150A1 (en) 2008-11-11 2011-09-14 Targacept Inc. Treatment with alpha 7-selective ligands
TW201031664A (en) * 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
JP2012533601A (ja) * 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用

Also Published As

Publication number Publication date
BR112015016994A8 (pt) 2018-01-23
JP6137336B2 (ja) 2017-05-31
CN105263492B (zh) 2018-04-10
CN105263492A (zh) 2016-01-20
WO2014111751A1 (en) 2014-07-24
CA2898043C (en) 2019-08-06
EP2945626A1 (en) 2015-11-25
KR101879921B1 (ko) 2018-07-18
MX2015009154A (es) 2016-03-04
JP2016504407A (ja) 2016-02-12
KR20150104632A (ko) 2015-09-15
BR112015016994A2 (pt) 2017-07-11
ES2701083T3 (es) 2019-02-20
EP2945626B1 (en) 2018-09-12
CA2898043A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
EP3630072A4 (en) METHODS AND COMPOSITIONS FOR TREATMENT OF EXCESSIVE Drowsiness
SG11201802144TA (en) Novel lactobacillus having various functions, and use thereof
IL283432A (en) Preparations, methods and systems for the treatment of skin disorders
EP3068289A4 (en) Prevention and treatment of bed exits, falls, and other conditions
ZA201903934B (en) Novel tnfr agonists and uses thereof
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
PH12015502788A1 (en) Antibody formulations and methods
EP2967978A4 (en) DEVICES, SYSTEMS AND METHOD FOR COOLING THE SKIN
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
EP2999421A4 (en) CRYOGENIC TREATMENT SYSTEMS
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
ZA201705254B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles
PL3274388T3 (pl) Urządzenia z akustyczną i termiczną izolacją na bazie lepkosprężystego poliuretanu
AU363883S (en) Tracking device
EP2961420A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING BARTH SYNDROME
HK1249851A1 (zh) 使用聚維酮碘的普通感冒的治療和預防
ZA201705222B (en) Block copolymers and the use thereof for improving the cold properties of fuels or combustibles
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
IL251880A0 (en) Preparations for the treatment of acute, post-operative or chronic pain and methods of using them
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
MX362819B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7 para el tratamiento de la narcolepsia.
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
EP3228677A4 (en) Friction resistance reducing agent and fire-extinguishing agent
SG11201601921RA (en) Azeotrope-like compositions of fo-e-1,3,4,4,4-pentafluoro-3-trifluoromethyl-1-butene and e-1-chloro-3,3,3-trifluoropropene and uses thereof
MX2018004091A (es) Antagonistas de il-17c para el tratamiento y/o prevencion de dermatitis atopica.

Legal Events

Date Code Title Description
FG Grant or registration